CytoMed Therapeutics Limited
GDTC
NASDAQ·Healthcare·Biotechnology·Mkt cap $10.2M
$0.90
▲ +6.75%
P/E
-2.87
Mkt Cap
$10.2M
52-Wk Range
$0.68–$3.68
52-Week Range
$0.68 - $3.68
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 55.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary gamma delta T cell engineering technology
- Dual approach combining gamma delta and NK cell functions
- iPSC platform for scalable cell therapy production
- Multi-cancer targeting capability through natural recognition systems
Bear Case
1 risk
- Low volatility (beta 0.0).
Growth
No forward estimates available
Clinical trial advancement of lead product CTM-N2D
Value
Valuation data unavailable
Momentum
Weak
-7.7% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying GDTC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
Most recent quarter reported revenue of $130.6K (+149% YoY). Reported EPS of -$0.11.
Reported EPS · last 4Q
Q4 25
-$0.11
Q3 25
-$0.06
Q2 25
-$0.07
Q1 25
-$0.07
Revenue trend · last 8Q
—
—
—
-38%
+20%
+28%
+45%
+149%
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
$83.1K
$82.7K
$108.6K
$52.4K
$100.0K
$105.7K
$161.2K
$130.6K
Margins · last 8Q
Gross
—
Profit
-1030.7%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How GDTC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related